ArticleThe Journal of experimental medicine2023
Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination.
Open access · hybridAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 41 citations in OpenAlex.
- Autoantibodies neutralizing type I interferons in COVID-19 patients from southern Brazil.Journal of human immunity · 2026Article
- CONSTANCES, the French nationwide population cohort: major accomplishments.European journal of epidemiology · 2026Article
- High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Article
- Review
- Variability in the TLR3 type I interferon pathway is predictive of RNA vaccine responses.Science advances · 2026Article
- Human antibodies against West Nile and related orthoflaviviruses.bioRxiv : the preprint server for biology · 2026Article
- High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.medRxiv : the preprint server for health sciences · 2026Article
- Multivalent display of envelope protein domain III with Mi3 nanoparticles induces protective immunity against lethal Zika virus infection in mice.Virologica Sinica · 2026Article
- TLR7 and TLR9 have overlapping but distinct roles in systemic lupus erythematosus and Sjögren's disease.Frontiers in immunology · 2026Review
- The seven enigmas of SARS-CoV-2: from the past to the future.Journal of human immunity · 2025Article
- Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection.The Journal of experimental medicine · 2025Article
- The monogenic landscape of human infectious diseases.The Journal of allergy and clinical immunology · 2025Review
- Learning from inborn errors of immunity and secondary immune deficiencies about vaccine immunogenicity, efficacy, and safety.Clinical and experimental immunology · 2025Review
- Aire Mutations and Autoimmune Diseases.Advances in experimental medicine and biology · 2025Review
- Distinct Inflammatory Programs Underlie the Intramuscular Lipid Nanoparticle Response.ACS nano · 2024Article
- Highly sensitive reporter cell line for detection of interferon types I-III and their neutralization by antibodies.European journal of immunology · 2024Article
- Incontinentia pigmenti underlies thymic dysplasia, autoantibodies to type I IFNs, and viral diseases.The Journal of experimental medicine · 2024Article
- Deficiency of Tlr7 and Irf7 in mice increases the severity of COVID-19 through the reduced interferon production.Communications biology · 2024Article
- Type I Interferon Autoantibodies Correlate With Cellular Immune Alterations in Severe COVID-19.The Journal of infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors at 20 institutions in 5 countries.
Aurélien Sokal *Necker Enfants Malades Institute, INSERM U1151/CNRS UMR 8253, Action thématique incitative sur programme-Avenir Team Auto-Immune and Immune B cell, University Paris Cité, University Paris-Est-Créteil, Créteil, France.ORCID 0000-0002-1198-8689
Paul Bastard *Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-5926-8437
Pascal Chappert *Necker Enfants Malades Institute, INSERM U1151/CNRS UMR 8253, Action thématique incitative sur programme-Avenir Team Auto-Immune and Immune B cell, University Paris Cité, University Paris-Est-Créteil, Créteil, France.ORCID 0000-0002-9799-4608
Giovanna Barba-Spaeth *Institut Pasteur, University Paris Cité, CNRS UMR 3569, Structural Virology Unit, Paris, France.ORCID 0000-0003-2069-9501
Slim FouratiVirology, Bacteriology, Hygiene and Mycology-Parasitology, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.ORCID 0000-0002-1236-5467
Alexis VanderbergheINSERM U955, team 2. Mondor Biomedical Research Institute, Paris-Est Créteil University, Créteil, France.ORCID 0000-0003-2447-3972
Pauline Lagouge-RousseyINSERM U955, team 2. Mondor Biomedical Research Institute, Paris-Est Créteil University, Créteil, France.ORCID 0000-0002-5736-8493
Isabelle MeytsDepartment of Immunology and Microbiology, Laboratory for Inborn Errors of Immunity, Department of Pediatrics, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium.ORCID 0000-0003-1214-0302
Adrian GervaisLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-1083-5787
Magali Bouvier-AliasVirology, Bacteriology, Hygiene and Mycology-Parasitology, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.ORCID 0000-0003-1590-5980
Imane AzzaouiINSERM U955, team 2. Mondor Biomedical Research Institute, Paris-Est Créteil University, Créteil, France.ORCID 0000-0001-5603-6780
Ignacio FernándezInstitut Pasteur, University Paris Cité, CNRS UMR 3569, Structural Virology Unit, Paris, France.ORCID 0000-0003-2632-8111
Andréa de la SelleNecker Enfants Malades Institute, INSERM U1151/CNRS UMR 8253, Action thématique incitative sur programme-Avenir Team Auto-Immune and Immune B cell, University Paris Cité, University Paris-Est-Créteil, Créteil, France.ORCID 0000-0002-9098-0107
Qian ZhangLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-9040-3289
Lucy BizienLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0001-9163-9122
Isabelle PellierPediatric Immuno-hemato-oncology Unit, Centre Hospitalier Universitaire Angers, Angers, France.ORCID 0000-0002-7988-4712
Agnès LinglartDepartement of Pediatric Endocrinology, Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris, Paris Saclay University, Le Kremlin-Bicêtre, France.ORCID 0000-0003-3455-002X
Anya RothenbuhlerDepartement of Pediatric Endocrinology, Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris, Paris Saclay University, Le Kremlin-Bicêtre, France.ORCID 0000-0001-9246-5160
Estelle MarcouxDepartment of Pediatrics, Nord Franche Comté Hospital, Trévenans, France.ORCID 0000-0003-3023-1697
Raphael AnxionnatDepartment of Pediatrics, Besançon Hospital, Besançon, France.ORCID 0000-0002-1152-7321
Nathalie CheikhDepartment of Pediatrics, Besançon Hospital, Besançon, France.ORCID 0000-0002-3403-3842
Juliane LégerDepartment of Pediatric Endocrinology and INSERM NeuroDiderot, Referral Centre for Endocrine, Growth and Development diseases, Assistance Publique-Hôpitaux de Paris Nord, University of Paris, Paris, France.ORCID 0000-0003-3708-7341
Blanca Amador-BorreroDepartment of Internal Medicine, Lariboisière University Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France.
Fanny FouyssacDepartment of Pediatric Hemato-oncology, Childrens Hospital, Nancy University Hospital, Nancy, France.
Vanessa MenutDepartment of Pediatrics, Mother-Child Hospital, Nantes, France.ORCID 0000-0002-7618-8965
Jean-Christophe GoffardDepartment of Internal Medicine, Université Libre de Bruxelles-Hôpitaux Universitaire de Bruxelles, Erasme Hospital, Bruxelles, Belgique.ORCID 0000-0002-2730-7673
Caroline StoreyDepartement of Pediatric Endocrinology, Robert Debré Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.ORCID 0000-0001-8633-2118
Caroline DemilyGénoPsy Referral Center, Centre de Référence de Maladies Rares Rare Disease with Psychiatric Epression, Le Vinatier Hospital, Bron, France.ORCID 0000-0003-3663-8447
Coralie MallebranchePediatric Immuno-hemato-oncology Unit, Centre Hospitalier Universitaire Angers, Angers, France.ORCID 0000-0002-8385-4057
Jesus TroyaDepartment of Internal Medicine, Infanta Leonor University Hospital, Madrid, Spain.ORCID 0000-0001-7323-114X
Aurora PujolNeurometabolic Diseases Laboratory, Institut d'Investigació Biomèdica de Bellvitge-Hospital Duran i Reynals, Centro de Investigación Biomédica en Red de Enfermededas Raras U759, and Catalan Institution of Research and Advanced Studies, Barcelona, Spain.ORCID 0000-0002-9606-0600
Marie ZinsUniversity of Paris, University of Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines, INSERM UMS11, Villejuif, France.ORCID 0000-0002-4540-4282
Pierre TiberghienFrench Blood Agency, La Plaine Saint-Denis, France.ORCID 0000-0002-9310-8322
Paul E GrayDepartment of Immunology and Infectious Diseases, Sydney Children's Hospital, Randwick, New South Wales, Australia.ORCID 0000-0003-2057-3968
Peter McNaughtonClinical Immunogenomics Research Consortium of Australasia, Sydney, Australia.ORCID 0000-0002-4600-8839
Anna SullivanClinical Immunogenomics Research Consortium of Australasia, Sydney, Australia.
Jane PeakeClinical Immunogenomics Research Consortium of Australasia, Sydney, Australia.ORCID 0000-0001-9003-5861
Romain LevyLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-6393-0198
Laetitia LanguilleDepartement of Internal Medicine, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.ORCID 0000-0001-8424-7550
Carlos Rodiguez-GallegoDepartment of Immunology, Hospital Universitario de G.C. Dr. Negrín, Canarian Health System, Las Palmas de Gran Canaria, Spain.
Bertrand BoissonLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0001-5240-3555
Sébastien GallienDepartment of Infectious Diseases, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.ORCID 0000-0002-8033-0936
Bénédicte NevenDepartment of Pediatric Immuno-Haematology and Rheumatology, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID 0000-0001-8941-0935
Marc MichelDepartement of Internal Medicine, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.
Bertrand GodeauDepartement of Internal Medicine, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.ORCID 0000-0002-6023-5990
Laurent AbelLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0001-7016-6493
Felix A ReyInstitut Pasteur, University Paris Cité, CNRS UMR 3569, Structural Virology Unit, Paris, France.ORCID 0000-0002-9953-7988
Jean-Claude WeillNecker Enfants Malades Institute, INSERM U1151/CNRS UMR 8253, Action thématique incitative sur programme-Avenir Team Auto-Immune and Immune B cell, University Paris Cité, University Paris-Est-Créteil, Créteil, France.ORCID 0000-0002-8284-0489
Claude-Agnès ReynaudNecker Enfants Malades Institute, INSERM U1151/CNRS UMR 8253, Action thématique incitative sur programme-Avenir Team Auto-Immune and Immune B cell, University Paris Cité, University Paris-Est-Créteil, Créteil, France.ORCID 0000-0002-4519-4473
Stuart G TangyeClinical Immunogenomics Research Consortium of Australasia, Sydney, Australia.ORCID 0000-0002-5360-5180
Jean-Laurent CasanovaLaboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.ORCID 0000-0002-7782-4169
Matthieu MahévasNecker Enfants Malades Institute, INSERM U1151/CNRS UMR 8253, Action thématique incitative sur programme-Avenir Team Auto-Immune and Immune B cell, University Paris Cité, University Paris-Est-Créteil, Créteil, France.ORCID 0000-0001-9182-1434
Inserm · FRCentre National de la Recherche Scientifique · FRUniversité Paris-Est Créteil · FRCentre Hospitalier Universitaire de Besançon · FRChildren’s Health Queensland Hospital and Health Service · AUHôpital Necker-Enfants Malades · FRUniversité Paris-Saclay · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Le Vinatier · FRCentre Hospitalier Régional et Universitaire de Nancy · FRGarvan Institute of Medical Research · AUHospital Universitario Infanta Leonor · ESHoward Hughes Medical Institute · USInstitut d'Investigació Biomédica de Bellvitge · ESKU Leuven · BEL'Hôpital Nord Franche-Comté · FRThe University of Queensland · AUUniversidad Fernando Pessoa Canarias · ESUniversité Libre de Bruxelles · BEUniversité Paris Cité · FR
Funding
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MMonogenic basis of resistance to SARS-CoV2 and predisposition to severe COVID-19R01AI088364 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Jean-Laurent Casanova, Shen-Ying Zhang · 2010 to 2026
$8.7MHoward Hughes Medical InstituteNCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI088364NIH HHS R01AI088364
Abstract
Inborn and acquired deficits of type I interferon (IFN) immunity predispose to life-threatening COVID-19 pneumonia. We longitudinally profiled the B cell response to mRNA vaccination in SARS-CoV-2 naive patients with inherited TLR7, IRF7, or IFNAR1 deficiency, as well as young patients with autoantibodies neutralizing type I IFNs due to autoimmune polyendocrine syndrome type-1 (APS-1) and older individuals with age-associated autoantibodies to type I IFNs. The receptor-binding domain spike protein (RBD)-specific memory B cell response in all patients was quantitatively and qualitatively similar to healthy donors. Sustained germinal center responses led to accumulation of somatic hypermutations in immunoglobulin heavy chain genes. The amplitude and duration of, and viral neutralization by, RBD-specific IgG serological response were also largely unaffected by TLR7, IRF7, or IFNAR1 deficiencies up to 7 mo after vaccination in all patients. These results suggest that induction of type I IFN is not required for efficient generation of a humoral response against SARS-CoV-2 by mRNA vaccines.
Indexed as
B-LymphocytesCOVID-19COVID-19 VaccinesInterferon Type IAntibodies, NeutralizingAntibodies, ViralAutoantibodiesHumansmRNA VaccinesSARS-CoV-2Spike Glycoprotein, CoronavirusToll-Like Receptor 7VaccinationAntibodies, NeutralizingAntibodies, ViralAutoantibodiesCOVID-19 VaccinesInterferon Type ImRNA VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Toll-Like Receptor 7
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.